Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine

Lupus

Volumn 26, Issue 10, 2017, Pages 1072-1081

  Nagel, J ^a   Saxne, T ^a   Geborek, P ^a   Bengtsson, A A ^a   Jacobsen, S ^b   Svaerke Joergensen, C ^c   Nilsson, J A ^a   Skattum, L ^d   Jonsen A ^a   Kapetanovic, M C ^a  

^a LUND UNIVERSITY   (Sweden)

^b University of Copenhagen   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

B cells; disease modifying anti rheumatic drugs (biologic); infection; Systemic lupus erythematosus; vaccination

Indexed keywords

AZATHIOPRINE; BELIMUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; METHOTREXATE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; 13-VALENT PNEUMOCOCCAL VACCINE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; IMMUNOASSAY; LABORATORY TEST; MALE; MIDDLE AGED; NONHUMAN; OPSONOPHAGOCYTIC ASSAY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VACCINATION; AGE; AGED; ANTIBODY PRODUCTION; CASE CONTROL STUDY; IMMUNOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PREDNISOLONE; VACCINATION; YOUNG ADULT;

EID: 85027554888     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317695465     Document Type: Article

References (38)

1. Zandman-Goddard G, Shoenfeld Y,. SLE and infections. Clin Rev Allergy Immunol 2003; 25: 29-40.
2. Abbas AK. Immunologic Tolerance and Autoimmunity. In: Abbas AK, Lichtman AH, Pillai H (eds) Cellular and Molecular Immunology. 8th ed. Philadelphia, USA: Elsevier Saunders, 2015, pp. 411-412.
3. Sun Y, Sun L,. CsBAFF, a Teleost B Cell Activating Factor, Promotes Pathogen-Induced Innate Immunity and Vaccine-Induced Adaptive Immunity. PLoS One 2015; 10: e0136015-e0136015.
4. Cancro MP, D'Cruz DP, Khamashta MA,. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119: 1066-1073.
5. Joyce S, Hui-Yuen XQ, Askanase L, et al. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskeletal Dis 2015; 7: 115-121.
6. Elbirt D, Asher I, Mahlab-Guri K, et al. Blys Levels in Sera of Patients with Systemic Lupus Erythematosus: Clinical and Serological Correlation. Isr Med Assoc J 2014; 16: 491-496.
7. Petri M, Stohl W, Chatham W, et al. Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus. Arthritis Rheum 2008; 58: 2453-2459.
8. Navarra SV, Guzmán RM, Gallacher AE, et al. for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
9. Furie R, Petri M, Zamani O, et al. for the BLISS-76 Study Group. A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus Erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
10. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39: 1632-1640.
11. Bingham CO, Winthrop KL, Yang L, et al. BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. Arthritis Res Ther 2015; 17: 347-347.
12. O'Neill SG, Isenberg DA,. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006; 15: 778-783.
13. Rahier J-F, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-1827.
14. Danza A, Ruiz-Irastorza G,. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013; 22: 1286-1294.
15. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus. Clin Infect Dis 2002; 34: 147-153.
16. ACIP CDC. Advisory Committee on Immunization Practices: Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm (accessed 24 May 2016).
17. WHO position paper-2012. Pneumococcal vaccines, 2012; 87: 129-144. http://www.who.int/wer/2012/wer8714/en/ (6 April 2012, accessed 24 May 2016).
18. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-422.
19. Clutterbuck EA, Lazarus R, Yu L-M, et al. Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. J Infect Dis 2012; 205: 1408-1416.
20. Lal G, Balmer P, Stanford E, et al. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005; 296: 135-147.
21. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010; 50: 329-337.
22. Song JY, Moseley MA, Burton RL, et al. Pneumococcal Vaccine and Opsonic Pneumococcal Antibody. J Infect Chemother 2013; 19: 412-425.
23. Anttila M, Voutilainen M, Jantti V, et al. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999; 118: 402-407.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
25. World Health Organization. The WHO consensus pneumococcal IgG ELISA. Training manual for enzyme-linked immunosorbent assay for the quantification of Streptococcus pneumonia serotype specific IgG (Pn PS ELISA): a guide to procedures for qualification of materials and analysis of assay performance. http://www.vaccine.uab.edu/ELISA%20Protocol.pdf (accessed 24 May 2016).
26. Martinez JE, Romero-Steiner S, Pilishvili T, et al. A Flow Cytometric Opsonophagocytic Assay for Measurement of Functional Antibodies Elicited after Vaccination with the 23-Valent Pneumococcal Polysaccharide Vaccine. Clin Diagn Lab Immunol 1999; 6: 581-586.
27. Jönsson G, Lood C, Gullstrand B, et al. Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. Clin Immunol 2012; 144: 214-227.
28. Granoff DM,. Assessing Efficacy of Haemophilus influenzae Type b Combination Vaccines. Clin Infect Dis 2001; 33: S278-S287.
29. Jódar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21: 3265-3272.
30. Gladman DD, Ibañez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
31. Fischer-Betz R, Schneider M,. for the Kommission Pharmakotherapie of DGRh. Recommendation for use of belimumab for systemic lupus erythematosus. Z Rheumatol 2013; 72: 462-467.
32. Kapetanovic MC, Roseman C, Jönsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011; 63: 3723-3732.
33. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000; 47: 247-257.
34. Patel AA, Swerlick RA, McCall CO,. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-389.
35. Doaty1 S, Agrawal H, Bauer E, et al. Infection and Lupus: Which Causes Which? Curr Rheumatol Rep 2016; 18: 13-13.
36. Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23: 231-269.
37. Nagel J, Geborek P, Saxne T, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther 2015; 19: 124-124.
38. Linton PJ, Dorshkind K,. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5: 133-139.